Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting

Ann Thorac Surg. 2003 Jul;76(1):124-8; discussion 128. doi: 10.1016/s0003-4975(03)00190-5.

Abstract

Background: We examined the effects of preoperative administration of enoxaparin (ENOX), a low-molecular-weight heparin, on bleeding indices and transfusion rates in patients undergoing coronary artery bypass grafting (CABG).

Methods: Patients undergoing isolated CABG between 1997 and 2002 who received preoperative ENOX or a continuous infusion of unfractionated heparin (UFH) were randomly divided into three groups: continuous UFH, ENOX last administered more than 12 hours before surgery (ENOX > 12), and ENOX administered less than 12 hours before surgery (ENOX < 12). Perioperative hemoglobin values, transfusion rates, and bleeding complications were compared.

Results: A total of 69, 58, and 34 patients comprised the UFH, ENOX > 12, and ENOX < 12 groups, respectively. Preoperative demographics and hematologic data were similar among the groups. Compared with the UFH group, the ENOX < 12 group had significantly lower postoperative hemoglobin values (9.6 +/- 1.3 g/dL versus 10.4 +/- 1.2 g/dL, p < 0.05), higher transfusion rates (73.5% versus 50.7%, p < 0.05), and required more total packed red cells per patient (882 +/- 809 mL versus 472 +/- 626 mL, p < 0.05). A nonsignificant increase was noted in the risk of returning to the operating room for bleeding in patients who had received ENOX compared with patients receiving UFH (6.5% versus 2.9%).

Conclusions: The preoperative use of ENOX less than 12 hours before CABG is associated with lower postoperative hemoglobin values and higher rates of transfusion than continuous UFH.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Blood Transfusion / statistics & numerical data*
  • Coronary Artery Bypass / methods*
  • Coronary Artery Bypass / mortality
  • Coronary Disease / diagnosis
  • Coronary Disease / mortality
  • Coronary Disease / surgery*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Enoxaparin / administration & dosage*
  • Enoxaparin / adverse effects
  • Female
  • Hemoglobins / analysis*
  • Heparin / administration & dosage
  • Heparin / adverse effects
  • Heparin, Low-Molecular-Weight / administration & dosage*
  • Heparin, Low-Molecular-Weight / adverse effects
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Postoperative Hemorrhage / etiology*
  • Postoperative Hemorrhage / therapy*
  • Preoperative Care / methods
  • Probability
  • Prognosis
  • Risk Assessment
  • Severity of Illness Index
  • Survival Rate
  • Treatment Outcome

Substances

  • Enoxaparin
  • Hemoglobins
  • Heparin, Low-Molecular-Weight
  • Heparin